Meeting
2019 ASCO Annual Meeting
In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.
Authors
Yen-Shen Lu
National Taiwan University Hospital, Taipei, Taiwan
Yen-Shen Lu , Sara A. Hurvitz , Fei Su , Wei He , Debu Tripathy , Saul Campos Gomez , Kyung Hae Jung , Marco Colleoni , Paul Wheatley-Price , Sherko Kuemmel , Nadia Harbeck , Fabio Andre Franke , Seock-Ah Im , Louis Chow , Tetiana Taran , Karen Rodriguez-Lorenc , Naveen Babbar , Aditya Bardia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Clinical Trial Registration Number
NCT02278120
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1018)
DOI
10.1200/JCO.2019.37.15_suppl.1018
Abstract #
1018
Poster Bd #
99
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis.
First Author: Sara A. Hurvitz
Poster
2023 ASCO Annual Meeting
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.
First Author: Tomás Pascual
Poster
2023 ASCO Annual Meeting
Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.
First Author: Seth Andrew Wander
Poster
2019 ASCO Annual Meeting
Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC).
First Author: Michelino DeLaurentiis